The potent pan-IP6K inhibitor LI-2242 ameliorates obesity, insulin resistance, and hepatic steatosis in DIO mice via a specific reduction in body fat and the improvement of insulin sensitivity. This evidence concerns the gene INS and fatty liver disease.